C4 Therapeutics, Inc. (CCCC) Covered Calls

C4 Therapeutics is a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD). Using its TORPEDO platform, it develops molecular glues and BiDAC degraders to destroy disease-causing proteins. The company focuses on oncology and neuro-inflammation, aiming to treat previously undruggable diseases.

You can sell covered calls on C4 Therapeutics, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for CCCC (prices last updated Tue 4:16 PM ET):

C4 Therapeutics, Inc. (CCCC) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
2.39 +0.09 2.38 2.43 6.1M - 0.2
Covered Calls For C4 Therapeutics, Inc. (CCCC)
Expiration Strike Call Bid Net Debit Return
If Flat		 Annualized
Return If Flat
Mar 20 2 0.30 2.13 -6.1% -89.1%
Apr 17 2 0.50 1.93 3.6% 24.8%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial

C4 Therapeutics, Inc. (NASDAQ: CCCC), based in Watertown, Massachusetts, is at the forefront of the targeted protein degradation (TPD) revolution. The company utilizes its proprietary TORPEDO® platform to design small molecules that harness the body’s natural protein recycling system. Unlike traditional drugs that merely inhibit a protein’s function, C4’s degraders—which include molecular glues and BiDAC™ (Bifunctional Degradation Activating Compounds)—aim to eliminate the target protein entirely. This catalytic mechanism provides the potential for more potent, durable, and selective therapies for patients facing cancers and other life-threatening diseases with high unmet medical needs.

Core Business and Products

  1. Cemsidomide (CFT7455): A potent, orally bioavailable molecular glue degrader targeting IKZF1/3. It is currently in the registrational Phase 2 MOMENTUM trial for relapsed/refractory multiple myeloma. It is designed to be a foundational therapy with potential for use across multiple lines of treatment.
  2. CFT1946 (BRAF V600 Degrader): This is a brain-penetrant BiDAC degrader targeting mutant BRAF V600. It is in Phase 1/2 clinical trials for solid tumors, including melanoma and colorectal cancer, specifically for patients who have developed resistance to traditional BRAF inhibitors.
  3. CFT8919 (EGFR L858R Degrader): An orally bioavailable allosteric degrader selective for the EGFR L858R mutation in non-small cell lung cancer. This program is being advanced in collaboration with Betta Pharmaceuticals to overcome resistance to existing EGFR-targeted therapies.
  4. TORPEDO® Platform: The company’s discovery engine integrates structural biology, chemistry, and informatics to optimize degrader design. It allows C4 to rapidly identify drug candidates with high catalytic activity and favorable pharmacokinetic properties.

Competitive Landscape

C4 Therapeutics competes in the highly specialized TPD field against other biotech pioneers and large pharmaceutical entities. Its primary peers in protein degradation include Arvinas, Inc. and Kymera Therapeutics. In the multiple myeloma and oncology sectors, it faces competition from established players such as Bristol-Myers Squibb and Pfizer. For its lung cancer and BRAF programs, it overlaps with Nurix Therapeutics and Revolution Medicines. C4 differentiates itself through its "Target-to-Lead" speed and a diversified portfolio that utilizes both molecular glues and heterobifunctional degraders.

Strategic Outlook and Innovation

C4’s 2026 strategy is anchored by the "MOMENTUM" registrational trial for cemsidomide, which management believes has best-in-class potential for treating multiple myeloma. The company is prioritizing this program to seek an accelerated approval pathway while simultaneously exploring combination therapies with BCMA-targeted agents. With a cash runway extending into late 2028, C4 is well-capitalized to reach significant clinical milestones and potentially transform into a commercial-stage organization. This financial stability allows for aggressive development of its oncology pipeline while maintaining independence in its core research initiatives.

Innovation at C4 is expanding beyond oncology into neuro-inflammation and neuro-degenerative diseases. The company is leveraging its expertise in brain-penetrant degraders to target proteins associated with Alzheimer’s and other central nervous system disorders. Furthermore, C4 continues to expand its strategic collaborations with industry giants like Merck KGaA, Biogen, and Roche, utilizing its TORPEDO platform to address their high-priority targets. By integrating AI-driven modeling to predict degrader-target interactions, C4 aims to shorten the development timeline for next-generation BiDACs, ensuring it remains a leader in the rapidly evolving TPD landscape.